Interleukin-24 inhibits cell migration and invasion in the neuroblastoma cell line SH-SY5Y

Zhuo,Baobiao; Wang,Rong; Zhang,Hongwei; Qin,Haihui; Yin,Yiyu; Shi,Yingchun

doi:10.3892/or.2013.2756

Interleukin-24 inhibits cell migration and invasion in the neuroblastoma cell line SH-SY5Y

Authors:
- Baobiao Zhuo
- Rong Wang
- Hongwei Zhang
- Haihui Qin
- Yiyu Yin
- Yingchun Shi
View Affiliations

Affiliations: Department of Surgery, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221006, P.R. China, Department of Ultrasound, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China
Published online on: September 30, 2013 https://doi.org/10.3892/or.2013.2756
Pages: 2749-2754

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastomas are common pediatric solid tumors with a variable clinical course; approximately 50% of patients present with metastatic disease at diagnosis. The development of metastatic lesions often causes a fatal outcome. Therefore, the prevention of metastases during the early stage of tumor development is critical for the improvement of the prognosis of neuroblastoma patients. We previously observed the suppression of neuroblastoma growth in response to overexpression of interleukin-24 (IL-24) in vitro and in vivo. IL-24 exerts its tumor-suppressive effects by multiple mechanisms, including the balance of Bcl-2 family proteins toward the pro-apoptotic pathway and the activation of the caspase cascade. In this study, we used adenovirus-mediated IL-24 (Ad-IL24) to examine the effect of the ectopic production of IL-24 on cell migration and invasion in human neuroblastoma cells. We found that IL-24 effectively inhibits SH-SY5Y neuroblastoma cell migration and invasion by changing subcellular localization and cellular levels of β-catenin and regulating the levels of proteins associated with cell migration and invasion. Thus, IL-24 should be considered a therapeutic agent that can inhibit primary neuroblastoma growth and that may prevent metastasis.

View Figures

View References

1	Schor NF: Neuroblastoma as a neurobiological disease. J Neurooncol. 41:159–166. 1999. View Article : Google Scholar : PubMed/NCBI
2	Maris JM: Recent advances in neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
3	Gustafson WC and Matthay KK: Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Rev Neurother. 11:1411–1423. 2011. View Article : Google Scholar : PubMed/NCBI
4	Isaacs H Jr: Fetal and neonatal neuroblastoma: retrospective review of 271 cases. Fetal Pediatr Pathol. 26:177–184. 2007. View Article : Google Scholar : PubMed/NCBI
5	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
6	Øra I and Eggert A: Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol. 21:217–228. 2011.PubMed/NCBI
7	Jiang H, Lin JJ, Su ZZ, Goldstein NI and Fisher PB: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 11:2477–2486. 1995.
8	Dent P, Yacoub A, Hamed HA, et al: The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther. 128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pataer A, Chada S, Roth JA, Hunt KK and Swisher SG: Development of Ad-mda7/IL-24-resistant lung cancer cell lines. Cancer Biol Ther. 7:103–108. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zheng M, Bocangel D, Ramesh R, et al: Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O⁶-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 7:3842–3851. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lebedeva IV, Su ZZ, Vozhilla N, et al: Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res. 68:7439–7447. 2008. View Article : Google Scholar
12	Park MA, Yacoub A, Sarkar D, et al: PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy. 4:513–515. 2008. View Article : Google Scholar : PubMed/NCBI
13	Yan S, Zhang H, Xie Y, et al: Recombinant human interleukin-24 suppresses gastric carcinoma cell growth in vitro and in vivo. Cancer Invest. 28:85–93. 2010. View Article : Google Scholar : PubMed/NCBI
14	Liu J, Sheng W, Xie Y, et al: The in vitro and in vivo antitumor activity of adenovirus-mediated interleukin-24 expression for laryngocarcinoma. Cancer Biother Radiopharm. 25:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
15	Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS and Fisher PB: The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA. 93:9160–9165. 1996. View Article : Google Scholar
16	Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC and Fisher PB: The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene. 21:708–718. 2002.PubMed/NCBI
17	Su ZZ, Lebedeva IV, Sarkar D, et al: Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene. 22:1164–1180. 2003.PubMed/NCBI
18	Zhuo B, Wang R, Yin Y, et al: Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo. Tumour Biol. 34:2419–2426. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM and Chada S: Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther. 9:510–518. 2004. View Article : Google Scholar : PubMed/NCBI
20	Fisher PB, Sarkar D, Lebedeva IV, et al: Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol. 224:300–307. 2007. View Article : Google Scholar : PubMed/NCBI
21	Fujioka T, Takebayashi Y, Kihana T, et al: Expression of E-cadherin and β-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep. 8:249–255. 2001.
22	Hugh TJ, Dillon SA, O’Dowd G, et al: β-catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer. 82:504–511. 1999.
23	Wang F, Nohara K, Olivera A, Thompson EW and Spiegel S: Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. Exp Cell Res. 247:17–28. 1999. View Article : Google Scholar : PubMed/NCBI
24	Neudauer CL and McCarthy JB: Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. Exp Cell Res. 286:128–137. 2003. View Article : Google Scholar : PubMed/NCBI
25	Goncharova EA, Ammit AJ, Irani C, et al: PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 283:L354–L363. 2002. View Article : Google Scholar : PubMed/NCBI
26	Kadri Z, Petitfrère E, Boudot C, et al: Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Cell Growth Differ. 11:573–580. 2000.PubMed/NCBI
27	Lakka SS, Jasti SL, Kyritsis AP, et al: Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. Clin Exp Metastasis. 18:245–252. 2000. View Article : Google Scholar
28	Ellerbroek SM, Halbleib JM, Benavidez M, et al: Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61:1855–1861. 2001.
29	Goldfarb RH and Liotta LA: Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost. 12:294–307. 1986. View Article : Google Scholar : PubMed/NCBI
30	Matrisian LM: The matrix-degrading metalloproteinases. Bioessays. 14:455–463. 1992. View Article : Google Scholar
31	Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 10:602–608. 1998. View Article : Google Scholar : PubMed/NCBI
32	Pritchard SC, Nicolson MC, Lloret C, et al: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy. Oncol Rep. 8:421–424. 2001.PubMed/NCBI
33	Nakopoulou L, Tsirmpa I, Alexandrou P, et al: MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat. 77:145–155. 2003. View Article : Google Scholar : PubMed/NCBI
34	Lu HF, Lai KC, Hsu SC, et al: Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem Res. 34:1575–1583. 2009. View Article : Google Scholar : PubMed/NCBI
35	Ribatti D, Surico G, Vacca A, et al: Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 68:1161–1168. 2001. View Article : Google Scholar : PubMed/NCBI
36	Ara T, Fukuzawa M, Kusafuka T, et al: Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg. 33:1272–1278. 1998. View Article : Google Scholar : PubMed/NCBI